News - Stryde Research

01 Milestone

First Patient Worldwide Dosed In A Phase 2 Angiokeratoma Trial

One of our sites became the first in the world to enroll and dose a patient in a Phase 2 angiokeratoma study.

02 Milestone

In a global lupus study, Stryde delivered one of only a handful of randomizations achieved anywhere so far.

03 Milestone

Stryde randomized its first patient in a skin cancer study testing a new, less invasive injection-based treatment.

04 Community

Our lupus team joined the Lupus Foundation of America's conference in Dallas to connect with patients and advocates.